Lower riskDrug recall · FDA · Published November 8, 2024
Accord Healthcare recalls Levothyroxine tablets with subpotent drug risk
Accord Healthcare recalls 1000-count levothyroxine tablets due to subpotent drug levels. This may not provide proper thyroid hormone treatment. Consumers should contact the manufacturer for details.
“Accord Healthcare recalls Levothyroxine tablets with subpotent drug risk.” GovInfoNow, updated September 23, 2026. https://govinfonow.com/recall/32453-accord-healthcare-recalls-levothyroxine-tablets-with-subpotent-drug-risk. Based on FDA recall #D-0076-2025 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0076-2025%22&limit=1).
Accord Healthcare, Inc. recalled Levothyroxine Sodium Tablets, USP, 75 mcg in 1000-count bottles due to subpotent drug risks, the Food and Drug Administration said on Nov. 8, 2024. The recall is classified as Class II.
How to tell if you have it
Brand: Accord Healthcare
Product: Levothyroxine Sodium Tablets, USP, 75 mcg (0.075 mg), 1000-count bottle, Rx Only
NDC: 16729-449-17
Lot #: D2300191
Expiration: 12/31/2025
Distribution: USA Nationwide
The hazard
The recalled Levothyroxine Sodium Tablets are subpotent, meaning they may not contain the expected amount of active ingredient. The FDA classified this as a Class II recall.
Context
GovInfoNow's records show Accord Healthcare, Inc. has 16 other recalls on record since Dec. 20, 2016. Other recent recalls of similar products include Accord Healthcare Levothyroxine Tablets Recall: Subpotent Drug Risk (Aug. 6, 2026), Accord Healthcare recalls Levothyroxine tablets with subpotent drug risk (June 8, 2026), and Accord Healthcare Levothyroxine Tablets Recall: Subpotent Risk (Sept. 16, 2025). Other recent recalls of similar products include Major Pharmaceuticals Levothyroxine Tablets Recall: Subpotent Drug Risk (July 13, 2026), Macleods Levothyroxine Tablets Recall: Subpotent Drug Risk (Feb. 26, 2026), and Vitruvias Thyroid Tablets Recall: Superpotent Drug Risk (Aug. 21, 2026).
How to tell if you have this one
Check for the 1000-count bottle labeled 'Levothyroxine Sodium Tablets, USP, 75 mcg (0.075 mg)' with NDC 16729-449-17. The lot number D2300191 was manufactured in the US for prescription use.
Brand
Accord Healthcare
Category
Drug
Based on the official FDA remedy
What to do — step by step
Check Prescription Details
Verify if you have a prescription for this specific levothyroxine product with the NDC code 16729-449-17.
Where it went and when
Where it was distributed
Distributed nationwide.
Nationwide
Not listed
FDA distribution: “USA Nationwide” States read from FDA’s own wording; “not listed” means the notice does not name it.
Distributed nationwide.
Recall timeline
FDA terminated this recall 22 months after the firm started it.
1Firm started the recall
2FDA classified it Class II
3Published in FDA’s Enforcement Report
4FDA terminated the recall
Dates from the agency record only; steps without a date are left out.
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
Official source: FDA Recall #D-0076-2025 (November 8, 2024) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0076-2025 to see it in context.
Plain-language summary written by qwen3:4b on September 23, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.